Sleep Interventions and Neurocognitive Outcomes in Amnestic Mild Cognitive Impairment

项目总结/摘要 这项拟议中的以患者为导向的指导研究职业发展奖（K23）将提供金贤， 博士，哥伦比亚大学博士后研究员，研究培训和职业发展，将 帮助她成为阿尔茨海默病和相关痴呆症的独立和专家睡眠科学家 （ADRD）研究。睡眠不好或断断续续会增加认知障碍和老年痴呆症的风险 淀粉样蛋白-β的积累、tau的扩散和加速的小胶质细胞活化可导致阿尔茨海默病（AD）。而 睡眠与大脑和认知功能的联系已被广泛确立，但目前还不清楚改变睡眠是否能改善大脑的认知功能。 老年人可以延缓认知能力下降，减缓AD的发展。了解睡眠的影响 认知变化的治疗可以增强目前对睡眠障碍的理解， 风险因素，并建立睡眠干预作为降低AD风险的潜在工具。的主要目的 一个被提议的研究项目是检查认知行为疗法的神经认知表现结果 失眠（CBTI）和声学慢波活动增强（SWAE）。治疗相关的机制 将使用客观和主观睡眠的变化来研究神经认知变化 参数第二个目的是检查睡眠治疗对认知介导的日常生活的影响。 功能探索性目的是评估CBTI和/或SWAE是否与血浆AD相关 生物标志物，即磷酸化tau。这些研究目标将得到职业发展的补充 计划涉及（1）提高睡眠和AD神经生物学的科学知识;（2）发展以下技能： 临床试验方法和相关的分析技能;（3）促进专业发展和网络， 睡眠和AD科学界。总的来说，拟议的研究，在其研究问题，范围， 结构，旨在作为未来R 01研究的路线图，研究复杂的关系 睡眠和ADRD之间的关系

Project Summary / Abstract This proposed Mentored Patient-Oriented Research Career Development Award (K23) will provide Hyun Kim, PhD, a post-doctoral fellow at Columbia University, with research training and career development that will help her become an independent and expert sleep scientist in Alzheimer's disease and related dementias (ADRD) research. Poor or fragmented sleep increases the risk of cognitive impairment and Alzheimer's disease (AD) through accumulation of amyloid-β, spread of tau, and accelerated microglial activation. While sleep's connection to brain and cognitive function is widely established, it is unclear whether modifying sleep in older adults could delay cognitive decline and slow the development of AD. Understanding the impact of sleep treatments on cognitive changes could enhance the current understanding of sleep disturbance as a modifiable risk factor and establish sleep interventions as a potential tool to reduce AD risks. The primary aim of the proposed research project is to examine neurocognitive performance outcomes of cognitive behavioral therapy for insomnia (CBTI) and acoustic slow wave activity enhancement (SWAE). The mechanism of treatment-related neurocognitive changes will be investigated using the changes in objective and subjective sleep parameters. The secondary aim is to examine the impact of sleep treatments on cognitively-mediated everyday functioning. The exploratory aim is to assess whether CBTI and/or SWAE are associated with plasma AD biomarker, namely phosphorylated tau. These research aims will be complemented by career development plans involving (1) enhancing scientific knowledge in sleep and AD neurobiology; (2) developing skills in clinical trial methodology and relevant analytic skills; (3) fostering professional development and networking in sleep and AD scientific community. Collectively, the proposed study, in its research question, scope, and structure, is designed to serve as a road map for future R01 studies that investigate the intricate relationship between sleep and ADRD.